PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings

LEATHERS, JAMES S.; BALDERRAMO, DOMINGO; PRIETO, JHON; DIEHL, FERNANDO; GONZALEZ-BALLERGA, ESTEBAN; FERREIRO, MELINA R.; CARRERA, ENRIQUE; BARREYRO, FERNANDO; DIAZ-FERRER, JAVIER; SINGH, DUPINDER; MATTOS, ANGELO Z.; CARRILHO, FLAIR; DEBES, JOSE D.

HEPATITIS MONTHLY

BAQIYATALLAH RESEARCH CENTER

Año: 2018 vol. 18

1735-143X

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally. Sorafenib, a multi-tyrosine kinase inhibitor, remains the standard of care for patients with inoperable or advanced-stage HCC. In resource-limited settings without access to surgical or locoregional therapy, sorafenib may be the only option for treating HCC. However, due to a modest survival benefit, as well as the limiting cost of sorafenib in certain regions, appropriate selection of patients for treatment is essential. Evaluation of Barcelona Clinic Liver Cancer (BCLC) criteria in resource-limited settings is frequently unachievable due to a variety of reasons. Using a cohort from the South American liver research network (1336 HCC cases), we created a cost-effective prognostic scoring system to help identify patients likely to have a survival benefit on sorafenib treatment, using simple laboratory variable